Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).

Munehide MatsuhisaMasato OdawaraTakahisa HiroseRyusuke Koshida Masayuki SendaYasushi TanakaYasuo Terauchi

Published in: Expert opinion on pharmacotherapy (2020)

Gla-300 showed no unprecedented safety concerns for insulin-experienced T1DM patients in Japanese clinical settings. Our results provide insights into strategies for blunted Gla-300 up-titration dose, despite insufficient HbA1c control and lifestyle modification.

Keyphrases

type diabetes
end stage renal disease
glycemic control
metabolic syndrome
public health
chronic kidney disease
cardiovascular disease
ejection fraction
physical activity
machine learning
prognostic factors
big data
deep learning